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We live in an era of increasing reliance on psychotropic
drugs. In particular, antidepressants, such as the Specific
Serotonin Reuptake Inhibitors (SSRIs), are among the most
widely used of all prescription drugs. A 2004 study
conducted by the Centers for Disease Control reported that
10% of American women and 4% of American men now
take antidepressants.
Although the SSRIs were initially conceived as a
treatment for depression per se, they are now expanding
into additional markets, so that they are increasingly
prescribed for a variety of ailments including anxiety, panic
attack, obsessive-compulsive disorder, alcoholism, drug
addiction, and eating disorders. In addition, the last decade
or so has seen their use substantially extended from the
adult population into school age and even preschool
children.
This “Prozac mania” has generated both exuberance and
condemnation in the public sphere, as evidenced in
numerous popular articles and books. Notable among these
are the best-selling “Listening to Prozac” by Peter Kramer
(Penguin, 1997), which exalts the benefits of SSRIs,
suggesting that they may have the ability to make many
of us “better than well”. Alternatively, concerns over
dangerous side effects, as well as philosophical concerns
related to the idea of finding happiness in a pill, have also
prompted cautionary popular works such as “Let them Eat
Prozac” by David Healy (New York University Press,
2004) and “The Prozac Backlash” by Joseph Glenmullen
(Simon and Schuster, 2000).
The scientific evidence to support the use (and FDA
approval) of these drugs comes primarily from Randomized
Controlled Trials, which are considered to be the gold
standard for testing drug efficacy and safety. This type of
study has several key features designed to ensure unbiased
assessment of the drug effect. First, the study participants
are randomly assigned to either a treatment (active drug) or
placebo condition. Additionally, this assignment is kept
secret from both the patient and the treating physician (i.e.,
the study is “double blind”). Thus, in principle, no biases
can be introduced either because of preferential assignment
of certain types of patients to the placebo versus treatment
group, or because of patient or physician expectations about
the drug efficacy. In addition, symptom assessment before
and during the drug treatment is typically accomplished, at
least in part, through the use of standard, objective tests
such as the Hamilton Depression Scale. This presumably
eliminates idiosyncrasies that could be introduced by
individual interviewers’ styles.
This use of Randomized Controlled Trials would seem to
provide for logically unassailable conclusions regarding
drug efficacy. Any statistically significant differences
between the drug and placebo groups must be caused by
the active drug ingredient itself.
In the position piece that follows, Cohen and Jacobs
provide detailed criticism of these procedures. They
question whether the studies are truly “blind”, and they
also challenge the use of so-called objective test proce-
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dures, which leave out any personal voice of the patients
themselves, do not allow for assessment of the full range of
psychoactive effects of the drugs, and may allow for
underreporting of adverse drug effects.
It should be noted that it was originally our intention to
present an accompanying paper to provide the opposing
view on this issue. Specifically, we made efforts to solicit a
paper defending the legitimacy of the empirical work using
Randomized Controlled Trials to demonstrate the efficacy
and safety of the SSRIs. However, our efforts in this were
unsuccessful. We encourage readers to contribute to this
aspect of the debate.
Debates in Neuroscience (2007) 1:42–43 43
